Stock Reports
Quote and News
Research Overview New
Research Archive
Stock Charts
Key Measures
Business Summary
Consensus Forecasts
Historical Financials
Dividend History Enhanced
Balance Sheet
Issued Capital New
Liquidity New
Peer Analysis New
Warrants New
Directors Interest
Substantial Shareholders
Interim Data
Announcements
Segment Performance
Stocks
ASX Market Report
Overseas Market Report
Introducing YMW
YMW Issue
Newsletter Archive
Research Archive
Recommendation Changes
Current Recommendations
New Analyst Searches Corporate Calendar Upcoming Dividends Upcoming Floats Stock Screener Featured Stock ASX300 News Digest Our Research Methodology
Special Reports
LICs
Hybrids
Technical Analysis
Funds
New Analyst Searches Corporate Calendar Upcoming Dividends Upcoming Floats Stock Screener Featured Stock ASX300 News Digest Our Research Methodology
Research Reports
All Analyst Reports
Star Ratings Limitations
Fund Times
Fund Archive
Fund Screener
About our Categories
Funds FAQ
ETFs
Tools
Portfolio
Portfolio Help
Stock Screener
Alerting Tool
Analyst stock searches
Fund Screener
Using the Fund Screener
SMSFs
News
Stocks
Special Reports
Funds
ETFs
Features
Hybrids
Technical Analysis
SMSFs
Learn
Fund Times
Ask the Analyst
China Wrap
About
Company News Summary
Phosphagenics Completes Pre-Clinical Study of Oxycodone/TPM Technology
20 Feb 2013 | 09:51:00 | Associate analysts | Increase | Decrease | 
Original announcement: Phosphagenics Further Expands Pain Portfolio
Phosphagenics has completed a pre-clinical study demonstrating that its oxycodone/TPM technology can reduce local pain without the need to deliver oxycodone into the bloodstream. The Company intends to commence clinical trials in Quarter 3 of 2013.
See more ASX300 News Announcements